PerspectiveCancer and Metabolism

Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet

See allHide authors and affiliations

Science Translational Medicine  20 Oct 2010:
Vol. 2, Issue 54, pp. 54ps50
DOI: 10.1126/scitranslmed.3001669

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Recurrent somatic mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes that result in the accumulation of D-2-hydroxyglutarate (D-2-HG) have been identified in malignant gliomas and in acute myeloid leukemia (AML). However, the function of this metabolite in normal and malignant tissues remains uncertain. A report in the current issue of Science describes a germline IDH2 mutation in a subset of patients with a rare metabolic disorder—D-2-hydroxyglutaric aciduria—that is similar to mutations seen in cancer patients. These observations further elucidate the effects of IDH mutations on normal and malignant cells.


  • Citation: N. Bhagwat, R. L. Levine, Metabolic syndromes and malignant transformation: Where the twain shall meet. Sci. Transl. Med. 2, 54ps50 (2010).

View Full Text

Stay Connected to Science Translational Medicine